Kuros Biosciences AG (CSBTF)
OTCMKTS · Delayed Price · Currency is USD
32.00
0.00 (0.00%)
Sep 4, 2025, 8:00 PM EDT
Kuros Biosciences AG Revenue
Kuros Biosciences AG had revenue of 63.48M CHF in the half year ending June 30, 2025, with 393.39% growth. This brings the company's revenue in the last twelve months to 103.35M, up 129.81% year-over-year. In the year 2024, Kuros Biosciences AG had annual revenue of 75.56M with 125.11% growth.
Revenue (ttm)
103.35M CHF
Revenue Growth
+129.81%
P/S Ratio
9.59
Revenue / Employee
847.14K CHF
Employees
122
Market Cap
1.25B USD
Revenue Chart
* This company reports financials in CHF.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 75.56M | 41.99M | 125.11% |
Dec 31, 2023 | 33.56M | 15.58M | 86.61% |
Dec 31, 2022 | 17.99M | 4.17M | 30.19% |
Dec 31, 2021 | 13.82M | 9.78M | 242.04% |
Dec 31, 2020 | 4.04M | 1.48M | 57.71% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Veradigm | 588.02M |
Elite Pharmaceuticals | 105.45M |
Tian'an Technology Group | 2.12M |
Glass House Brands | 221.55M |
Northwest Biotherapeutics | 1.09M |
American Oncology Network | 1.76B |
Silence Therapeutics | 27.17M |
Longduoduo Company | 4.99M |